BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Buy” from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average rating of “Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.
A number of brokerages have recently weighed in on BCRX. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Sunday, May 28th. Finally, Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th.
ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/14/biocryst-pharmaceuticals-inc-nasdaqbcrx-receives-consensus-rating-of-buy-from-analysts.html.
BioCryst Pharmaceuticals (BCRX) traded down 0.86% during midday trading on Friday, reaching $5.79. 142,537 shares of the company were exchanged. BioCryst Pharmaceuticals has a one year low of $2.85 and a one year high of $9.25. The firm’s market cap is $465.63 million. The firm’s 50-day moving average is $5.65 and its 200-day moving average is $6.50.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The business had revenue of $9.40 million during the quarter, compared to analysts’ expectations of $6.13 million. During the same period in the previous year, the company earned ($0.31) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 95.8% on a year-over-year basis. On average, equities analysts expect that BioCryst Pharmaceuticals will post ($0.73) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its position in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares during the last quarter. Comerica Bank boosted its position in BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 2,552 shares during the last quarter. Fox Run Management L.L.C. bought a new position in BioCryst Pharmaceuticals during the second quarter valued at approximately $126,000. Bank of America Corp DE boosted its position in BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock valued at $210,000 after buying an additional 7,568 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in BioCryst Pharmaceuticals during the first quarter valued at approximately $337,000. Hedge funds and other institutional investors own 84.45% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.